HIV drug shows promise to reboot immune system in Non-Responders

NCT ID NCT07637877

Recruiting now Disease control Sponsor: Beijing 302 Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests whether adding the HIV drug rilpivirine to standard treatment can help people with HIV whose immune systems haven't fully recovered. About 21 adults with low CD4 counts despite years of successful viral suppression will receive rilpivirine for 48 weeks. The goal is to see if it can reduce hidden HIV reservoirs and increase CD4 immune cells, potentially improving long-term health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOLOGICAL NON-RESPONDERS IN PEOPLE WITH HIV

Contacts and locations

Locations

302 Hospital
RECRUITING

Beijing, 100039, China
Guangzhou Eighth People's Hospital
RECRUITING

Guangzhou, China
Shenzhen Third People's Hospital
RECRUITING

Shenzhen, China
The Fifth Medical Center of PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100039, China
The Third Affiliated Hospital of Sun Yat-sen University
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.